Medication info
Janumet XR Extended Release Tablets 50/1000 Milligrams

Janumet XR Extended Release Tablets 50/1000 Milligrams

Prescription medicationTabletOral
Ingredient · strength
Sitagliptin Hydrochloride Hydrate›56.7mg / 1 tabletMetformin Hydrochloride›1000mg / 1 tablet
Manufacturer / importer
HLB Pharma Co., Ltd.
Appearance
Light green, oval-shaped, bi-convex extended-release film-coated tablet
Packaging
28 tablets/bottle, 56 tablets/bottle, 200 tablets/bottle
Approval status
Active

MFDS item code 202202072 · Approved 2022.05.17 · Insurance code 647304420

Summary

Main use
Improvement of glycemic control in type 2 diabetes mellitus
Who takes it
Adults
Adult dose
In antidiabetic therapy, the dose of this medicine should be determined based on each patient’s current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended daily doses of each component: sitagliptin 100 mg and metformin 2000 mg. To reduce gastrointestinal adverse reactions caused by metformin, this medicine should be taken with a meal once daily, preferably in the evening, and the dose should be increased gradually. The dose of this medicine 100/1000 mg extended-release tablets is 1 tablet once daily. Patients taking this medicine 50/500 mg extended-release tablets or 50/1000 mg extended-release tablets should take 2 tablets together once daily. 1. Patients not currently receiving metformin: For patients with no previous experience of antidiabetic drug therapy who do not achieve adequate glycemic control with monotherapy, or for patients who cannot achieve adequate glycemic control with sitagliptin monotherapy, the initial total daily dose of this medicine is sitagliptin 100 mg and metformin 1000 mg. If adequate glycemic control cannot be achieved with the initial dose, the dose may be increased gradually up to the maximum recommended daily dose of metformin 2000 mg to reduce gastrointestinal adverse reactions caused by metformin. 2. Patients receiving metformin: - For patients who cannot achieve adequate glycemic control with metformin monotherapy, the recommended initial total daily dose of this medicine is sitagliptin 100 mg and the patient’s current metformin dose. - Patients switching from combination therapy with sitagliptin and metformin to this medicine may start at their current doses of sitagliptin and metformin. - Patients previously taking immediate-release tablets at a dose of 850 mg or 1000 mg twice daily as their current metformin dose may start with this medicine 50/1000 mg extended-release tablets at a dose of 2 tablets once daily. 3. Patients who cannot achieve adequate glycemic control with combination therapy of metformin and a sulfonylurea, metformin and insulin, or metformin and a thiazolidinedione: The initial total daily dose of this medicine is sitagliptin 100 mg, and the initial dose of metformin should be determined taking the patient’s blood glucose level and current dose into consideration. The dose should be increased gradually to reduce gastrointestinal adverse reactions caused by metformin. When coadministered with a sulfonylurea or insulin, a reduction in the dose of the sulfonylurea or insulin may be considered to reduce the risk of hypoglycemia induced by the sulfonylurea or insulin. Patients with renal impairment This medicine may be used in patients with moderate renal impairment, stage 3a (creatinine clearance [CrCl] ≥ 45 and <60 mL/min or estimated glomerular filtration rate (eGFR) ≥ 45 and <60 mL/min/1.73m2), who do not have other symptoms that may increase the risk of lactic acidosis, with the following dose adjustment. Treatment should not be initiated with this medicine, as the starting dose of metformin is 500 mg or 850 mg once daily. The maximum recommended dose of metformin is 1000 mg daily. Renal function should be monitored carefully every 3-6 months. If renal function decreases to CrCl <45 mL/min or eGFR <45 mL/min/1.73m2, this medicine must be discontinued immediately.

Ingredients

Manufacturer
HLB Pharma Co., Ltd.

Efficacy & effects

Improvement of glycemic control in type 2 diabetes mellitus

View approved original text

This medication helps control blood sugar levels in patients with type 2 diabetes when taken together with sitagliptin and metformin. When combined with diet and exercise, blood sugar levels can be effectively managed. This helps stabilize blood sugar fluctuations and reduce the risk of complications. Therefore, this medication is used to enhance blood sugar control in patients with type 2 diabetes.

How to take

Adult dose

In antidiabetic therapy, the dose of this medicine should be determined based on each patient’s current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended daily doses of each component: sitagliptin 100 mg and metformin 2000 mg. To reduce gastrointestinal adverse reactions caused by metformin, this medicine should be taken with a meal once daily, preferably in the evening, and the dose should be increased gradually. The dose of this medicine 100/1000 mg extended-release tablets is 1 tablet once daily. Patients taking this medicine 50/500 mg extended-release tablets or 50/1000 mg extended-release tablets should take 2 tablets together once daily. 1. Patients not currently receiving metformin: For patients with no previous experience of antidiabetic drug therapy who do not achieve adequate glycemic control with monotherapy, or for patients who cannot achieve adequate glycemic control with sitagliptin monotherapy, the initial total daily dose of this medicine is sitagliptin 100 mg and metformin 1000 mg. If adequate glycemic control cannot be achieved with the initial dose, the dose may be increased gradually up to the maximum recommended daily dose of metformin 2000 mg to reduce gastrointestinal adverse reactions caused by metformin. 2. Patients receiving metformin: - For patients who cannot achieve adequate glycemic control with metformin monotherapy, the recommended initial total daily dose of this medicine is sitagliptin 100 mg and the patient’s current metformin dose. - Patients switching from combination therapy with sitagliptin and metformin to this medicine may start at their current doses of sitagliptin and metformin. - Patients previously taking immediate-release tablets at a dose of 850 mg or 1000 mg twice daily as their current metformin dose may start with this medicine 50/1000 mg extended-release tablets at a dose of 2 tablets once daily. 3. Patients who cannot achieve adequate glycemic control with combination therapy of metformin and a sulfonylurea, metformin and insulin, or metformin and a thiazolidinedione: The initial total daily dose of this medicine is sitagliptin 100 mg, and the initial dose of metformin should be determined taking the patient’s blood glucose level and current dose into consideration. The dose should be increased gradually to reduce gastrointestinal adverse reactions caused by metformin. When coadministered with a sulfonylurea or insulin, a reduction in the dose of the sulfonylurea or insulin may be considered to reduce the risk of hypoglycemia induced by the sulfonylurea or insulin. Patients with renal impairment This medicine may be used in patients with moderate renal impairment, stage 3a (creatinine clearance [CrCl] ≥ 45 and <60 mL/min or estimated glomerular filtration rate (eGFR) ≥ 45 and <60 mL/min/1.73m2), who do not have other symptoms that may increase the risk of lactic acidosis, with the following dose adjustment. Treatment should not be initiated with this medicine, as the starting dose of metformin is 500 mg or 850 mg once daily. The maximum recommended dose of metformin is 1000 mg daily. Renal function should be monitored carefully every 3-6 months. If renal function decreases to CrCl <45 mL/min or eGFR <45 mL/min/1.73m2, this medicine must be discontinued immediately.

Precautions

This medication is used for the treatment of diabetes and contains two components: sitagliptin and metformin. First, an allergic reaction may occur when taking this medication, so if symptoms such as rash, hives, or difficulty breathing develop, discontinue use immediately and consult a physician. Second, acute pancreatitis, which is inflammation of the pancreas, may occur, so if symptoms such as abdominal pain, vomiting, or nausea appear, inform medical staff immediately. Third, due to the metformin component, rare but serious lactic acidosis may occur; if symptoms such as muscle pain, weakness, difficulty breathing, or abdominal pain arise, seek medical attention immediately. Fourth, this medication should not be taken by patients with decreased kidney function, severe infection, dehydration, congestive heart failure, or acute diseases such as myocardial infarction. Fifth, the use of iodine contrast agents for examinations around the time of this medication should be temporarily suspended, and the medication may be resumed only after confirming normal kidney function. Sixth, pregnant women or women who may become pregnant, as well as nursing mothers, should not take this medication. Seventh, caution is advised due to the increased risk of hypoglycemia or lactic acidosis resulting from irregular meals, intense exercise, or interactions with other medications. Eighth, it is important to regularly monitor kidney function, blood tests, and vitamin B12 levels while taking this medication. Ninth, alcohol may increase the risk of side effects from this medication, so it is advisable to avoid drinking alcohol while on this medication. Finally, the safety of this medication in children has not been established, and elderly patients require dose adjustments and caution based on kidney function.

Side effects

Severe allergic reactions, anaphylaxis, angioedema, Stevens-Johnson syndrome, acute pancreatitis, lactic acidosis, hypoglycemia, diarrhea, upper respiratory tract infection, headache, nausea, vomiting, abdominal pain, nasopharyngitis, constipation, arthralgia with severe and disabling symptoms, bullous pemphigoid, myalgia, limb pain, back pain, interstitial lung disease, pruritus, thrombocytopenia, rhabdomyolysis, elevated liver enzymes, acute kidney failure, cutaneous vasculitis, rash, urticaria

Not everyone experiences these, and they can vary from person to person.

Storage

This medication should be stored in a tightly closed container to prevent air or moisture from entering. It is best to store it at room temperature between 1 and 30 degrees Celsius. This will help maintain the medication's effectiveness and ensure safe usage.

Appearance and packaging

Appearance

Light green, oval-shaped, bi-convex extended-release film-coated tablet

Package unit

28 tablets/bottle, 56 tablets/bottle, 200 tablets/bottle

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.